Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.810 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
ROSEN, A TOP RANKED FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Analyst Expectations for BioXcel Therapeutics's Future ↗
 
Via Benzinga
News headline image
A Preview Of BioXcel Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Why BioXcel Therapeutics Stock Flopped Again Today ↗
Major changes are afoot with the company, and few are happy about them. 
Via The Motley Fool
News headline image
Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy ↗
Mizuho analyst Graig Suvannavejh downgraded BioXcel Therapeutics, Inc. (NASDAQ: BTAI) to Neutral from Buy,  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023 ↗
 
Via Benzinga
News headline image
NVIDIA To Rally More Than 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
B of A Securities lowered the price target for Valero Energy Corporation (NYSE: BMBL) from $160 to $152. B of A Securities analyst Doug Leggate downgraded the stock from Buy to Neutral. Valero Energy... 
Via Benzinga
News headline image
ROSEN, A LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations
From Gibbs Law Group
Via Business Wire
News headline image
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
News headline image
3 Biotech Stocks to Sell in August Before They Crash and Burn ↗
These biotech stocks are set to crash and burn, so it's probably a good idea for investors to sell in August, before it's too late. 
Via InvestorPlace
News headline image
US Stocks Turn Higher; BioXcel Therapeutics Shares Plummet ↗
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 80 points on Monday. The Dow traded up 0.01% to 35,284.34 while the NASDAQ rose 0.64% to 13,732.05.... 
Via Benzinga
Topics Stocks
News headline image
Why BioXcel Therapeutics Stock Is Getting Crushed Today ↗
BioXcel just announced a big change. 
Via The Motley Fool
News headline image
CLF Stock Alert: U.S. Steel Rejects Cleveland-Cliffs Bid ↗
Cleveland-Cliffs (CLF) stock is worth checking on today after the company's takeover bill for United States Steel (X) was rejected. 
Via InvestorPlace
News headline image
FFIE Stock Alert: Faraday Future Delivers Its First FF 91 ↗
Faraday Future (FFIE) stock is a hot topic on Monday after the EV company delivered its first FF 91 2.0 Futurist Alliance. 
Via InvestorPlace
News headline image
PYPL Stock Alert: What to Know as PayPal Names New CEO ↗
PayPal (PYPL) stock is in the news Monday as investors react to the finance transfer company naming Alex Chriss as its next CEO. 
Via InvestorPlace
News headline image
Why Is BioXcel Therapeutics (BTAI) Stock Down 46% Today? ↗
BioXcel Therapeutics (BTAI) stock is taking a beating on Monday after the biopharmaceutical company announced major layoffs. 
Via InvestorPlace
News headline image
Dow Falls 50 Points; Monday.com Posts Upbeat Results ↗
U.S. stocks traded mostly lower this morning, with the Dow Jones falling around 50 points on Monday. Following the market opening Monday, The Dow traded down 0.14% to 35,230.38 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
BTAI DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
WHY: New York, NY - (NewMediaWire) - August 13, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December... 
Via TheNewswire.com
Topics Lawsuit
News headline image
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
WHY: New York, NY - (NewMediaWire) - August 12, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December... 
Via TheNewswire.com
Topics Lawsuit
News headline image
ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GDS, Arrow, ImmunityBio, and BioXcel and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ: BTAI Investor Notice Lawsuit Alleges Securities Laws Violations by BioXcel Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 08/11/2023 -- An investor, who purchased shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI), filed a lawsuit over alleged violations of Federal Securities Laws by BioXcel... 
Via SBWire
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.